-
Virology and epidemiology
Dengue virus serotypes, Aedes mosquito transmission, endemic regions, risk factors, and secondary infection.
-
Pathogenesis
Viremia, immune response, antibody-dependent enhancement, capillary leak, thrombocytopenia, and shock.
-
Clinical features and phases
Febrile, critical, and recovery phases; typical symptoms, rash, and severe dengue.
-
Warning signs and severity classification
WHO classification: dengue without warning signs, dengue with warning signs, and severe dengue.
-
Diagnosis
Clinical suspicion, CBC and hematocrit trends, NS1 antigen, RT-PCR, IgM/IgG serology, and differential diagnosis.
-
Management
Outpatient care, monitoring, fluid management principles, admission criteria, management of shock and bleeding, and drugs to avoid.
-
Special situations
Dengue in children, pregnancy, older adults, and people with comorbidities.
-
Prevention and public health
Personal bite prevention, vector control, surveillance, and vaccines.
The period around defervescence, often days 3-7 of illness, can be the highest-risk period. Falling platelet count alone does not define severity. Clinical warning signs, rising hematocrit with evidence of plasma leakage, perfusion, urine output, and overall clinical status guide management. There is no routine specific antiviral treatment; careful supportive care and appropriate fluid therapy are the basis of treatment. The
CDC clinical guidance outlines this risk-based approach.